Navigation Links
Hope for major advance in fighting world killer disease

University of Leicester scientists are heading a worldwide research project which could revolutionise the diagnosis and treatment of diarrhoea in children in developing countries.

The four-year project, the results of which are now being piloted in four hospitals in India, will offer a means of identifying the two most deadly forms of the disease quickly, cheaply and with little training necessary for practitioners.

The implications for improving children's health could be enormous. Diarrhoea is a major killer in developing countries. World Health Organisation statistics indicate that more than 2 million people die each year from the effects of diarrhoea, most of them children under five years old.

Diarrhoea is caused by a range of bacterial, viral and parasitic organisms, and is usually spread by contaminated water and poor sanitation. Two particular bacteria , enteropathogenic E.coli (EPEC), which causes a persistent infection lasting more than 14 days, and Shigella, the cause of dysentery - are the most deadly in terms of killing children. They cause only 20% of cases of diarrhoea but result in 60% of deaths. It is these two killers - EPEC and Shigella - that the Leicester-led project is targeting.

Peter Williams, Professor of Microbiology in the Department of Genetics, and Leicester colleagues Uta Praekelt and Marie Singer, are working with scientists at the Robert Koch Institute in Germany and Anna University in Chennai India, and with doctors at the Christian Medical College in Vellore, India, and at Gadjah Mada University in Yogyakarta, Indonesia.

Their project, called the European-Asian Challenge to Childhood Diarrhoea, or EACh-ChilD (because each child is precious!) currently receives funding of ?m from the European Union, but in its earlier stages it was supported by an Academic Links Scheme funded by the British Council and the Indian University Grants Commission.

Professor Williams commented: "All cases of diarrhoea look the same to start with, and children are usually given oral rehydration therapy, which is cheap and puts back fluids lost by diarrhoea. But disease caused by EPEC and Shigella does not usually respond to oral rehydration therapy. They are much more severe forms of the disease and even if they don't kill they can often inflict irreversible damage that interferes with the child's growth and development.

"Current practice in most Indian clinics is only to test for E. coli and Shigella if the child's symptoms have not responded to oral rehydration therapy by three days. The usual tests then take a further three days, by which time the disease may have progressed to a very serious stage. Our project has been to design a rapid method to identify these two types of the disease so that doctors can focus treatment immediately on those children who need it, before the damage is done.

"It's often said that, if a medical intervention costs more than US$½ it's not going to be viable in developing countries. Our test is quick, robust and cheap. At a workshop we held recently at Anna University, more than 30 people, ranging from technicians and students to clinical professors, had the opportunity to perform the tests with their own hands and see the results with their own eyes. They were very impressed!"

In the developing world it is not possible on cost grounds to give antibiotics to every child with diarrhoea, and in any case antibiotics would not work in every case. The Leicester test includes the facility to determine antibiotic resistance profiles quickly so that the correct antibiotics can be used.

With basic equipment donated by the EACh-ChilD project, the test is now being piloted in four hospitals in south India, one of which, the Government Children's Hospital in Chennai, is the biggest children's hospital in Asia. Once any further improvements are made following these trials, then Professor William s expects the technique to spread round other clinicians in the region and elsewhere. His team has already received enquiries from the Gambia in Africa.

A commercial testing kit is currently being developed.


Source:University of Leicester

Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. Researchers uncover sequence of major rice pathogen
3. Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed
4. Biochemists report discovery of structure of major piece of telomerase; implications for cancer
5. Virologists make major step towards understanding the process of HIV infection
6. Biota makes major antiviral discovery
7. New gene scanning technology marks a major advance in disease research
8. LIAI scientists make major finding on potential smallpox treatment
9. MicroRNAs have shaped the evolution of the majority of mammalian genes
10. MIT: Oceans are a major gene swap-meet for plankton
11. U-M scientists identify major psoriasis susceptibility gene
Post Your Comments:

(Date:11/17/2015)... SOUTH EASTON, Mass. , Nov. 17, 2015 /PRNewswire/ ... "Company"), a leader in the development and sale of ... to the worldwide life sciences industry, today announced it ... closing of its $5 million Private Placement (the "Offering"), ... Offering to $4,025,000.  One or more additional closings are ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... 24, 2015  Twist Bioscience, a company focused ... Ph.D., Twist Bioscience chief executive officer, will present ... December 1, 2015 at 3:10 p.m. Eastern Time at The ... --> --> ... Bioscience is on Twitter. Sign up to follow ...
(Date:11/24/2015)... Vancouver, BC (PRWEB) , ... November 24, 2015 ... ... to our customer, OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology ... Creation Technologies’ Texas facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device ...
(Date:11/24/2015)... , Nov. 24, 2015 HemoShear ... on discovering drugs for metabolic disorders, announced today ... to its Board of Directors (BOD). Mr. Watkins ... of Human Genome Sciences (HGS), and also served ... Jim Powers , Chairman and CEO ...
(Date:11/24/2015)... ... November 24, 2015 , ... Whitehouse Laboratories is pleased to announce ... stand-alone facility will be strictly dedicated to basic USP 61, USP 62 and USP ... chance to have complete chemistry and micro testing performed by one supplier. Management ...
Breaking Biology Technology: